Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Company profile
Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dynavax GmbH ...
IRS number
330728374
DVAX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Dynavax Reports First Quarter 2023 Financial Results
2 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
23 Feb 23
CT ORDER
Confidential treatment order
24 Jan 23
8-K
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
9 Jan 23
Transcripts
DVAX
Earnings call transcript
2023 Q1
2 May 23
DVAX
Earnings call transcript
2022 Q4
23 Feb 23
DVAX
Earnings call transcript
2022 Q3
4 Nov 22
DVAX
Earnings call transcript
2022 Q2
5 Aug 22
DVAX
Earnings call transcript
2022 Q1
6 May 22
DVAX
Earnings call transcript
2021 Q4
28 Feb 22
DVAX
Earnings call transcript
2021 Q3
5 Nov 21
DVAX
Earnings call transcript
2021 Q2
5 Aug 21
DVAX
Earnings call transcript
2021 Q1
7 May 21
DVAX
Earnings call transcript
2020 Q4
26 Feb 21
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 174.56 mm | 174.56 mm | 174.56 mm | 174.56 mm | 174.56 mm | 174.56 mm |
| Cash burn (monthly) | 9.22 mm | 422.92 k | 10.08 mm | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 20.93 mm | 960.25 k | 22.89 mm | n/a | n/a | n/a |
| Cash remaining | 153.63 mm | 173.60 mm | 151.67 mm | n/a | n/a | n/a |
| Runway (months of cash) | 16.7 | 410.5 | 15.0 | n/a | n/a | n/a |
Institutional ownership, Q1 2023
| 13F holders | Current |
|---|---|
| Total holders | 212 |
| Opened positions | 27 |
| Closed positions | 48 |
| Increased positions | 62 |
| Reduced positions | 86 |
| 13F shares | Current |
|---|---|
| Total value | 1.19 tn |
| Total shares | 131.56 mm |
| Total puts | 46.30 k |
| Total calls | 175.80 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 18.88 mm | $185.17 bn |
| FHI Federated Hermes | 12.66 mm | $124.15 bn |
| STT State Street | 8.94 mm | $87.74 bn |
| Vanguard | 8.45 mm | $82.90 bn |
| Deep Track Capital | 6.35 mm | $62.29 bn |
| Chicago Capital | 5.85 mm | $57.34 bn |
| Bain Capital Life Sciences Fund | 4.91 mm | $76.74 mm |
| BAC Bank Of America | 4.34 mm | $42.58 bn |
| Fisher Asset Management | 3.96 mm | $38.89 mm |
| Bain Capital Life Sciences Investors | 3.92 mm | $39.33 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 May 23 | Cano Francis | Common Stock | Grant | Acquire A | No | No | 0 | 5,357 | 0.00 | 31,548 |
| 26 May 23 | Cano Francis | Stock Options Common Stock | Grant | Acquire A | No | No | 11.2 | 22,500 | 252.00 k | 22,500 |
| 26 May 23 | Eastland Julia Marie | Common Stock | Grant | Acquire A | No | No | 0 | 5,357 | 0.00 | 10,714 |
| 26 May 23 | Eastland Julia Marie | Stock Option Common Stock | Grant | Acquire A | No | No | 11.2 | 22,500 | 252.00 k | 22,500 |
| 26 May 23 | Kisner Daniel L | Common Stock | Grant | Acquire A | No | No | 0 | 5,357 | 0.00 | 12,214 |
| 26 May 23 | Kisner Daniel L | Stock Option Common Stock | Grant | Acquire A | No | No | 11.2 | 22,500 | 252.00 k | 22,500 |
| 26 May 23 | Brent MacGregor | Common Stock | Grant | Acquire A | No | No | 0 | 5,357 | 0.00 | 10,714 |
| 26 May 23 | Brent MacGregor | Stock Option Common Stock | Grant | Acquire A | No | No | 11.2 | 22,500 | 252.00 k | 22,500 |
| 26 May 23 | Peter R. Paradiso | Common Stock | Grant | Acquire A | No | No | 0 | 5,357 | 0.00 | 13,714 |
| 26 May 23 | Peter R. Paradiso | Stock Option Common Stock | Grant | Acquire A | No | No | 11.2 | 22,500 | 252.00 k | 22,500 |
News
5 Value Stocks In The Healthcare Sector
29 May 23
JMP Securities Maintains Outperform on Dynavax Technologies, Lowers Price Target to $24
3 May 23
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $27 Price Target
3 May 23
Dynavax Technologies Q1 EPS $(0.19) Misses $(0.13) Estimate, Sales $46.92M Beat $38.59M Estimate
2 May 23
Press releases
Dynavax to Present at Upcoming Investor Conferences
30 May 23
Dynavax to Present at the JMP Securities Life Sciences Conference
8 May 23
Dynavax Reports First Quarter 2023 Financial Results
2 May 23
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
18 Apr 23